Real-world, 12-month results demonstrated efficacy, safety and durability for faricimab as a treatment for retinal vein ...

Retinal vein occlusion (RVO) is a severe disease that occurs when a vein in the light-sensitive layer at the back of the eye ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that new long-term data for the company's Vabysmo showed sustained retinal drying and vision improvements in Retinal Vein Occlusion.

An FDA target action date of August 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application ...

June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...

European Commission grants marketing approval for Eylea 8 mg to treat macular edema following RVO, including branch, central and hemiretinal vein occlusion: Berlin Monday, January ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...

The European Commission has granted marketing authorization for Eylea 8mg (aflibercept 8mg, 114.3mg/ml solution for injection ...

Please provide your email address to receive an email when new articles are posted on . In this expert perspective, Manjot K. Gill, MD, discusses faricimab for the management of retinal vein occlusion ...

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...